SHLTN.SW
SHL Telemedicine Ltd. [SHLTN.SW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SHLTN.SW Stock Summary
Top SHLTN.SW Correlated Resources
SHLTN.SW
Top 10 Correlated ETFs
SHLTN.SW
Top 10 Correlated Stocks
SHLTN.SW
In the News
SHLTN.SW Financial details
SHLTN.SW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.56 | 4.65 | 3.99 | 3.82 | 0.47 | |
| Net income per share | 0.23 | 0.97 | 0.54 | 0.03 | -0.13 | |
| Operating cash flow per share | 1.13 | 1.21 | 1.03 | 0.45 | 0 | |
| Free cash flow per share | 0.98 | 1.1 | 0.85 | 0.28 | -0.03 | |
| Cash per share | 0.99 | 0.84 | 0.58 | 1.01 | 0.31 | |
| Book value per share | 2.78 | 3.59 | 3.31 | 3.61 | 0.54 | |
| Tangible book value per share | 0.27 | 1.42 | 1.16 | 1.43 | 0.02 | |
| Share holders equity per share | 2.78 | 3.59 | 3.31 | 3.61 | 0.54 | |
| Interest debt per share | 1.48 | 0.12 | 0.03 | 0.26 | 0.41 | |
| Market cap | 80.78M | 63.02M | 67.22M | 112.38M | 1.81B | |
| Enterprise value | 89.5M | 59.52M | 61.14M | 110.57M | 1.83B | |
| P/E ratio | 33.55 | 6.21 | 11.8 | 404.25 | -128.61 | |
| Price to sales ratio | 2.16 | 1.29 | 1.6 | 2.8 | 36.6 | |
| POCF ratio | 6.82 | 4.94 | 6.2 | 24 | 9.81K | |
| PFCF ratio | 7.89 | 5.48 | 7.57 | 38.62 | -590.55 | |
| P/B Ratio | 2.77 | 1.67 | 1.93 | 2.97 | 31.92 | |
| PTB ratio | 2.77 | 1.67 | 1.93 | 2.97 | 31.92 | |
| EV to sales | 2.39 | 1.22 | 1.46 | 2.75 | 36.96 | |
| Enterprise value over EBITDA | 10.35 | 3.77 | 6.81 | 20.44 | 769.27 | |
| EV to operating cash flow | 7.56 | 4.67 | 5.64 | 23.62 | 9.9K | |
| EV to free cash flow | 8.74 | 5.17 | 6.89 | 38 | -596.29 | |
| Earnings yield | 0.03 | 0.16 | 0.08 | 0 | -0.01 | |
| Free cash flow yield | 0.13 | 0.18 | 0.13 | 0.03 | 0 | |
| Debt to equity | 0.05 | 0 | 0 | 0 | 0.5 | |
| Debt to assets | 0.55 | 0.32 | 0.42 | 0.42 | 0.53 | |
| Net debt to EBITDA | 1.01 | -0.22 | -0.68 | -0.33 | 7.41 | |
| Current ratio | 0.84 | 1.43 | 1.11 | 1.24 | 2.64 | |
| Interest coverage | 1.15 | 36.1 | 19.57 | 2.33 | -0.05 | |
| Income quality | 4.92 | 1.26 | 1.91 | 16.84 | -0.01 | |
| Dividend Yield | 0 | 0 | 0.16 | 0 | 0 | |
| Payout ratio | 0 | 0 | 1.84 | 0 | 0 | |
| Sales general and administrative to revenue | 0.07 | 0.05 | 0.07 | 0.1 | 0.08 | |
| Research and developement to revenue | -0.03 | 0 | 0.06 | -0.01 | -0.01 | |
| Intangibles to total assets | 0.4 | 0.41 | 0.38 | 0.35 | 0.45 | |
| Capex to operating cash flow | -0.14 | -0.1 | -0.18 | -0.38 | -17.61 | |
| Capex to revenue | -0.04 | -0.03 | -0.05 | -0.04 | -0.07 | |
| Capex to depreciation | -0.35 | -0.31 | -0.5 | -0.36 | -0.61 | |
| Stock based compensation to revenue | 0 | 0.01 | 0.01 | 0 | 0.03 | |
| Graham number | 3.79 | 8.83 | 6.35 | 1.47 | 1.28 | |
| ROIC | 0.04 | 0.3 | 0.12 | 0.02 | 0 | |
| Return on tangible assets | 0.06 | 0.31 | 0.15 | 0.01 | -0.2 | |
| Graham Net | -2.36 | -0.79 | -1.75 | -1.49 | -0.33 | |
| Working capital | -5.12M | 6.95M | 1.34M | 3.44M | 28.5M | |
| Tangible asset value | 2.87M | 14.92M | 12.22M | 15.04M | 2.47M | |
| Net current asset value | -8.49M | 5.41M | -11.44M | -9M | -22.97M | |
| Invested capital | 0.49 | 0.02 | 0 | 0.06 | 0.57 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.29M | 1.35M | 1.37M | 1.63M | 2.26M | |
| Average inventory | 1.79M | 1.34M | 1.25M | 1.37M | 2.79M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 19.66 | 21.1 | 22.23 | 30.4 | 42.14 | |
| Days of inventory on hand | 45.31 | 25.5 | 22.51 | 25.65 | 61.38 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 18.56 | 17.3 | 16.42 | 12 | 8.66 | |
| Inventory turnover | 8.05 | 14.31 | 16.22 | 14.23 | 5.95 | |
| ROE | 0.08 | 0.27 | 0.16 | 0.01 | -0.25 | |
| Capex per share | -0.15 | -0.12 | -0.19 | -0.17 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2015-06-30 for Q2
| Metric | History | 2014-06-30 | 2014-09-30 | 2014-12-31 | 2015-03-31 | 2015-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.3 | 0.78 | 0.87 | 0.93 | 1.11 | |
| Net income per share | 0.01 | 0.02 | 0.05 | 0.14 | -0.12 | |
| Operating cash flow per share | -0.11 | 0.01 | 0.01 | -0.06 | 0.48 | |
| Free cash flow per share | -0.22 | -0.1 | -0.12 | -0.13 | 0.38 | |
| Cash per share | 2.59 | 1.51 | 1.7 | 0.9 | 1.22 | |
| Book value per share | 8.71 | 4.95 | 5.9 | 5.81 | 5.89 | |
| Tangible book value per share | 4.56 | 4.95 | 3.14 | 2.5 | 2.58 | |
| Share holders equity per share | 8.71 | 4.95 | 5.9 | 5.81 | 5.89 | |
| Interest debt per share | 3.48 | 1.89 | 2.22 | 2.14 | 2.21 | |
| Market cap | 66.36M | 103.2M | 93.6M | 84.15M | 101.92M | |
| Enterprise value | 85.35M | 123.27M | 113.42M | 101.1M | 116.02M | |
| P/E ratio | 210 | 100 | 47.85 | 14.73 | -20.42 | |
| Price to sales ratio | 6.46 | 10.31 | 10.34 | 8.84 | 8.81 | |
| POCF ratio | -74.98 | 1.27K | 1.56K | -135.95 | 20.24 | |
| PFCF ratio | -38.03 | -84.11 | -73.7 | -64.24 | 25.89 | |
| P/B Ratio | 0.96 | 1.62 | 1.52 | 1.42 | 1.66 | |
| PTB ratio | 0.96 | 1.62 | 1.52 | 1.42 | 1.66 | |
| EV to sales | 8.31 | 12.31 | 12.54 | 10.62 | 10.03 | |
| Enterprise value over EBITDA | 40.16 | 126.56 | 215.23 | 51.32 | 86.65 | |
| EV to operating cash flow | -96.44 | 1.52K | 1.89K | -163.33 | 23.04 | |
| EV to free cash flow | -48.91 | -100.46 | -89.31 | -77.18 | 29.48 | |
| Earnings yield | 0 | 0 | 0.01 | 0.02 | -0.01 | |
| Free cash flow yield | -0.03 | -0.01 | -0.01 | -0.02 | 0.04 | |
| Debt to equity | 0.24 | 0.23 | 0.21 | 0.2 | 0.19 | |
| Debt to assets | 0.35 | 0.34 | 0.33 | 0.35 | 0.36 | |
| Net debt to EBITDA | 8.93 | 20.6 | 37.62 | 8.61 | 10.53 | |
| Current ratio | 2.46 | 2.59 | 2.45 | 1.86 | 1.82 | |
| Interest coverage | 0.19 | 0.43 | -7.84 | 10.56 | -0.56 | |
| Income quality | -11.2 | 0.31 | 0.12 | -0.43 | -4.04 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.2 | 0.19 | -0.36 | 0.07 | 0.24 | |
| Research and developement to revenue | 0.06 | 0.06 | -0.35 | 0.06 | 0.04 | |
| Intangibles to total assets | 0.31 | 0 | 0.31 | 0.37 | 0.36 | |
| Capex to operating cash flow | 0.97 | -16.15 | -22.17 | 1.12 | -0.22 | |
| Capex to revenue | -0.08 | -0.13 | -0.15 | -0.07 | -0.1 | |
| Capex to depreciation | -0.61 | 0 | 0 | 0 | -0.66 | |
| Stock based compensation to revenue | 0.01 | 0 | 0 | 0 | 0.01 | |
| Graham number | 1.4 | 1.49 | 2.5 | 4.28 | 3.99 | |
| ROIC | 0 | 0 | 0.01 | 0.02 | -0.01 | |
| Return on tangible assets | 0 | 0 | 0.01 | 0.02 | -0.02 | |
| Graham Net | -2.05 | -0.93 | -1.14 | -2.14 | -1.91 | |
| Working capital | 27.51M | 25.57M | 23.77M | 15.46M | 16.13M | |
| Tangible asset value | 36.02M | 0 | 32.68M | 25.49M | 26.87M | |
| Net current asset value | 8.92M | 9.14M | 9.41M | 1.36M | 1.9M | |
| Invested capital | 0.39 | 0.38 | 0.38 | 0.36 | 0.36 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.43M | 2.02M | 1.93M | 1.81M | 2.1M | |
| Average inventory | 2.92M | 3.06M | 3.34M | 3.23M | 3.53M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 39.3 | 23.64 | 21.54 | 17.05 | 19.95 | |
| Days of inventory on hand | 32.5 | 38.99 | 54.41 | 52.05 | 43.28 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.29 | 3.81 | 4.18 | 5.28 | 4.51 | |
| Inventory turnover | 2.77 | 2.31 | 1.65 | 1.73 | 2.08 | |
| ROE | 0 | 0 | 0.01 | 0.02 | -0.02 | |
| Capex per share | -0.11 | -0.1 | -0.13 | -0.07 | -0.11 |
SHLTN.SW Frequently Asked Questions
What is SHL Telemedicine Ltd. stock symbol ?
SHL Telemedicine Ltd. is a IL stock and trading under the symbol SHLTN.SW
What is SHL Telemedicine Ltd. stock quote today ?
SHL Telemedicine Ltd. stock price is $13.8 today.
Is SHL Telemedicine Ltd. stock public?
Yes, SHL Telemedicine Ltd. is a publicly traded company.
Company Profile
- Volume Average 2.57K
- Market Capitalization 210.73M
- Employee 448
- CEO Mr. Erez Nachtomy
- Headquarters Tel Aviv,IL
- IPO Date 2000-11-15
-
Website
https://www.shl-telemedicine.com 
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.
